

Ana Fernández Montes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9398167/publications.pdf>

Version: 2024-02-01

25
papers

432
citations

759233

12
h-index

752698

20
g-index

27
all docs

27
docs citations

27
times ranked

694
citing authors

#	ARTICLE	IF	CITATIONS
1	Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. <i>British Journal of Cancer</i> , 2017, 117, 775-782.	6.4	77
2	Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. <i>British Journal of Cancer</i> , 2017, 116, 1526-1535.	6.4	46
3	Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1191-1198.	1.0	42
4	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3889.	2.4	35
5	Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. <i>Cancer Medicine</i> , 2019, 8, 882-889.	2.8	28
6	On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1379-1388.	4.9	19
7	Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. <i>Oncologist</i> , 2019, 24, e687-e695.	3.7	19
8	Optimism and social support as contributing factors to spirituality in Cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 3367-3373.	2.2	18
9	Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMENON National Cancer Registry. <i>Gastric Cancer</i> , 2018, 21, 96-105.	5.3	16
10	Breast cancer patient experiences through a journey map: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0257680.	2.5	16
11	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020, 19, 165-177.	2.3	15
12	Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis. <i>Journal of Geriatric Oncology</i> , 2018, 9, 254-264.	1.0	14
13	Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. <i>Clinical and Translational Oncology</i> , 2020, 22, 351-359.	2.4	14
14	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. <i>PLoS ONE</i> , 2020, 15, e0235848.	2.5	14
15	Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 543-553.	2.3	14
16	Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. <i>Scientific Reports</i> , 2021, 11, 14321.	3.3	8
17	Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol. <i>PLoS ONE</i> , 2020, 15, e0244355.	2.5	8
18	SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 658-669.	2.4	8

#	ARTICLE	IF	CITATIONS
19	External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?. <i>Gastric Cancer</i> , 2021, 24, 445-456.	5.3	7
20	Insights into the Use of Peripherally Acting μ -Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice. <i>Current Treatment Options in Oncology</i> , 2021, 22, 26.	3.0	4
21	Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. <i>Clinical and Translational Oncology</i> , 2021, 23, 1520-1528.	2.4	4
22	Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry. <i>Biomedicines</i> , 2022, 10, 148.	3.2	4
23	Do Clinical Trials Meet Current Care Needs? Views of Digestive Oncology Specialists in Galicia (Spain) Using the Delphi Method. <i>Healthcare (Switzerland)</i> , 2021, 9, 665.	2.0	0
24	Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2022, , 1.	2.4	0
25	SEOM clinical guidelines (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 611-612.	2.4	0